Heart attack drug shows promise in cutting cholesterol and inflammation
NCT ID NCT03515304
First seen Dec 16, 2025 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tested whether evolocumab, a drug that lowers cholesterol, can also reduce inflammation and heart damage after a certain type of heart attack (NSTEMI). Sixty adults who had a recent heart attack received either evolocumab or a placebo. The main goals were to see changes in LDL cholesterol and inflammation in the heart. Results help understand if this drug can improve recovery, but it is not a cure and ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Steven Paul Schulman
Baltimore, Maryland, 21136, United States
Conditions
Explore the condition pages connected to this study.